Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

NCT07424222 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Interventions

DRUG: Ruxolitinib

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]